Overall, these findings suggest that pharmacological modulation of GDF15 shows promise for the treatment of obesity and its complications, such as type 2 diabetes mellitus (T2DM). This evidence concerns the gene GDF15 and obesity due to melanocortin 4 receptor deficiency.